bluuebunny/crossref_metadata_2025_split huggingface dataset:
Association of mucin production and survival in colon cancer.
Authors: Hogan John , Samaha Georges , Burke John , Waldron David , Condon Eoin , Coffey John Calvin 
Published: February 2017

512 Background: Debate persists regarding the relationship between mucin production and cancer-related outcome following curative resection for colon cancer. Lack of consensus is due to (amongst other factors) discrepancies in definition, small cohort studies and the integration of both colon and rectal cancers. This study characterizes the relationship between mucin production and cancer-related outcome in an homogenous single-institute based cohort. Methods: A database spanning demographics, clinico-pathologic characteristics and prognostic factors was generated for all patients undergoing curative-intent colonic resection in the interval 2000 to 2010. Patients were categorized simply as mucin producing (i.e. MC) or non-mucin producing adenocarcinoma (NMC). Primary outcomes included overall survival (time to death from any cause) and disease free survival (time to loco-regional and systemic recurrence). Trends were established for MC and NMC using Kaplan-Meier estimates, plotted and compared using log-rank analysis. Findings significant on univariate analysis were incorporated into multivariate analysis. Cox proportional hazards model was employed to determine the associated hazard of both death and disease recurrence in each group. Statistical analysis was performed using R version 2.15. P < 0.05 was considered significant. Results: 77 mucinous carcinomas (MC) and 358 non mucinous carcinomas (NMC) were included. On univariate analysis, MC was associated with improved overall survival (OS) (P=0.007). Both N1 (HR 1.625, P=0.011) and N2 (HR 2.7, P<0.001) status were associated with adverse OS. On multivariate analysis, MC approached but did not reach statistical significance for improved OS (HR 0.543, P=0.061). A comparison of Kaplan-Meier estimates for overall survival in MC and NMC groups indicated that OS was significantly improved in the MC cohort (P=0.011). There was no difference in disease free survival (P=0.224). Systemic recurrence was greater in the NMC group (P=0.042). Conclusions: Mucin production in colonic adenocarcinoma appears associated with improved overall but not disease-free survival. In addition, the absence of mucin was associated with adverse systemic but not local recurrence.
Impact of smoking history on patient outcome following hepatic metastasectomy for colorectal cancer.
Authors: Shen Yehua , Sahin Ibrahim Halil , Hassan Manal , Kee Bryan K. , Feig Barry W. , Ellis Lee M. , Aloia Thomas A. , Abdalla Eddie K. , Curley Steven A. , Vauthey Jean-Nicolas , Garrett Chris R. 
Published: February 2017

517 Background: Although it is clear that smoking increases perioperative risks associated with liver resection, there are also oncologic concerns associated with smoking. For example, nicotine induces CRC cell proliferation in vitro. We undertook a single institution retrospective analysis of pts outcome based on prior smoking history. Methods: Under an IRB-approved protocol, pts who underwent hepatic metastasectomy for treatment for CRC liver metastasis with curative intent at a single institution, from 2005 to 2009, were retrospectively evaluated for smoking history, time to progression (TTP), and overall survival (OS). Pts were analyzed as never smokers (A), ex-smokers (B), or current smokers and those who discontinued at the time of cancer diagnosis (C). Results: 350 pts outcomes were analyzed; their data is demonstrated in the table below. There were no difference in TTP or OS between group A and B (p = 0.346, p = 0.453 respectively). Pts in group A had a superior TTP and OS when compared to group C (p =0.002, p = 0.021 respectively). Patients in group B had a superior TTP when compared to group C (p =0.044), while a difference of OS was not found between the two groups (p =0.153). Conclusions: Smoking history is a negative prognostic factor for TTP in patients undergoing hepatic metastasecomy for CRC. Further studies are necessary to validate these preliminary findings. Active smokers who are candidates for hepatic metastasectomy for CRC should undergo nicotine cessation counseling and treatment. [Table: see text]
Survival differences in patients (pts) with resected rectal cancer who received neoadjuvant therapy with or without postoperative chemotherapy (CT).
Authors: Wu Christina Sing-Ying , Wei Lai , Glass Katherine , Wilson John , Abdel-Misih Sherif , Martin Ludmila Katherine , Haraldsdottir Sigurdis , Harzman Alan , Husain Syed , Schmidt Carl Richard , Arnold Mark , Goldberg Richard M. , Bekaii-Saab Tanios S. 
Published: February 2017

518 Background: Pts with stage II/III rectal cancers are treated with neoadjuvant chemoradiation and surgical resection followed by adjuvant CT per practice guidelines. It is unclear whether adjuvant CT provides survival benefit, and the purpose of this study was to measure outcome in pts who did and did not receive adjuvant CT. Methods: We used a prospectively collected database for pts treated at The Ohio State University, and analyzed overall survival (OS), time to recurrence (TTR), pt characteristics, tumor features, and treatments. Survival curves were estimated using Kaplan-Meier method and compared by the log-rank test. Age was compared using the Wilcoxon test, and other categorical variables were compared using Chi-square test or Fisher’s exact test. Results: Between August 2005 to July 2011, 110 pts were identified and 71 pts had received adjuvant CT. There was no significant difference in sex, race, pathologic tumor (T) stage, and pathologic complete response between the two pt groups. Pts receiving adjuvant CT were significantly younger (median age 54.3 vs. 62 years, p=0.01) and had more advanced pathologic nodal (N) stage (43 vs. 19%, p=0.02). Median OS was 72.6 months with CT vs. 36.4 months without CT (p=0.0003). Median TTR has not yet been reached. Conclusions: In this retrospective analysis, adjuvant CT was associated with a longer OS despite more advanced pathologic nodal staging. Prospective randomized studies are warranted to determine whether adjuvant CT provides a survival benefit for pts across the spectrum of stage II and III rectal cancer. [Table: see text]
Intensity-modulated radiation therapy (imrt) for anal cancer: Results from a multi-institutional retrospective cohort study.
Authors: Call Jason Andrew , Prendergast Brendan M , Jensen Lindsay G , Ord Celine B , Goodman Karyn A. , Jacob Rojymon , Mell Loren K. , Thomas Charles R. , Jabbour Salma , Miller Robert Clell 
Published: February 2017

523 Background: This study was done to assess the toxicity and efficacy of IMRT for anal cancer in a multi-institutional setting. Methods: Records of 152 total patients (pts) were reviewed retrospectively. Data on disease control and toxicity were collected as well as pt and treatment characteristics. Acute (<6 months) and late (>=6 months) severe toxicity (grade >=3) were recorded at each institution. Four were excluded for either presence of metastatic disease (2) or stage TX (2). There was data for late toxicity on 120 pts. Results: T stage was T1 in 28, T2 in 79, T3 in 29 and T4 in 12 pts. N stage was N0 in 77, N1 in 40, N2 in 19 and N3 in 12 pts. The median age was 56 yrs and median follow-up was 26.8 months. Cumulative IMRT dose was 51.25 Gy (median) (range: 4.32-61.2 Gy) in a median of 28 fractions (2-34). Chemotherapy was given in all but 2 pts and the most common regimen was 5- fluorouracil plus mitomycin-C. The median total elapsed treatment time was 40 days. Local control at 3 yrs was 87% and was significantly worse for patients with T3-4 disease (79% vs 90% at 3 years; p=0.04). There was no correlation between dose and local control. Regional control, distant control and overall survival were 97%, 91%, and 87% at 3 yrs, respectively. Nodal status was associated with regional and distal control as well as overall survival (p<0.01 for each). The most common acute severe toxicity was hematologic (41%). Severe acute GI, skin or other toxicity was 11%, 20% and 1% respectively. There were two grade 5 toxicities (hematologic and GI). Severe late toxicity was limited to skin (1%) and GI (3%). Conclusions: IMRT resulted in excellent local control in this multi-institutional cohort of pts. Although T stage did predict for worse local control, most pts with T3-4 disease were controlled with IMRT. Nodal status predicts for regional and distal control as well as overall survival. Severe toxicity was acceptable with this technique.
Final report of post-marketing survey of panitumumab in Japanese patients with unresectable advanced or recurrent colorectal cancer.
Authors: Hamaguchi Tetsuya , Boku Narikazu , Sugihara Kenichi , Kitagawa Yuko , Takiuchi Hiroya , Hatake Kiyohiko , Muro Kei , Yoshino Takayuki , Yamazaki Naoya , Gemma Akihiko , Yana Ikuo , Ueno Hiroshi , Ohtsu Atsushi 
Published: February 2017

525 Background: Panitumumab (P-mab) was approved in Japan in Apr. 2010 for the treatment of unresectable, advanced or recurrent colorectal cancer with wild-type KRAS, both in monotherapy and in combination with chemotherapy for all lines of treatment. All-case surveillance of P-mab was conducted to assess safety and efficacy in practical use since clinical data on Japanese patients were limited. Methods: All patients were registered before starting P-mab containing therapy by central registration method since the launch of P-mab in Japan. Patients were examined for eligibility requirements such as KRAS genotype (wild), ECOG PS (0-2) and interstitial pneumonitis (-). Skin disorder, infusion reaction(IR), electrolyte abnormality, cardiac disorder, interstitial lung disease (ILD) were surveyed with special interest. Results: 3,091 patients were registered from Jun. 2010 to Nov. 2010 and interim analysis were made with 3,005 patients at the point of Oct. 2011. The interim analysis; male: 63.6%, mean age: 65 y.o., KRAS wild/ mutant/ not determinable: 97.3%/0.1%/2.6%. Proportion of first line/second line/third line or later treatment: 10.4%/18.0%/71.6%, PS 0-1/2/3/4: 91.3%/7.9%/0.7%/0.1%. P-mab monotherapy/combination: 41.0%/58.8%. Combination regimens: FOLFOX/FOLFIRI/other regimens: 18.7%/33.4%/15.2%. Overall incidence of ADRs:83.7 %, and that of Grade 3 or higher ADRs:24.7 %. Incidence of ADRs of special interest: skin disorder 77.8%, IR 1.5%, electrolyte abnormality18.3%, cardiac disorder 0.2%, ILD 1.3% (0.6% fatal). Incidences of ILD were similar in monotherapy and in combination. The median survival time of patients with P-mab monotherapy as third line or later treatment was 10.3 months, 95%CI (9.0-11.3). Result of final analysis with 3086 patients(99.8% of registerd patients) at the point of Jun. 2012 is to be presented in this meeting. Conclusions: The safety profile of P-mab in the post-marketing use was similar to that previously reported in the clinical trials. The risk/benefit balance for use of P-mab in patients with unresectable colorectal cancer remains favorable.
Phase II study of S-1 plus leucovorin (1-week treatment regimen followed by 1-week rest period) in patients with untreated metastatic colorectal cancer in Japan and China: Comparing results of each country and updating overall survival.
Authors: Xu Ruihua , Li Jin , Xu Jianming , Denda Tadamichi , Ikejiri Koji , Shen Lin , Baba Hideo , Toh Yasushi , Shimada Ken , Kato Takeshi , Sakai Kenji , Matsuyama Ayumi , Mishima Hideyuki , Wang Jin-Wan 
Published: February 2017

528 Background: We previously reported results of a phase II study of the S-1 plus oral Leucovorin(LV) (1 week on/ 1 week off) for patients (pts) with metastatic Colorectal Cancer (mCRC) (Denda et al. Gastrointestinal Cancers Symposium 2012). This study showed promising activity in pts with mCRC. We report here the comparison of efficacy and safety data of each country, and updated Overall Survival (OS). Methods: Pts were eligible as follows: histologically confirmed adenocarcinoma, age ≥20, ECOG PS 0-1, no prior chemotherapy, at least one measurable lesion by RECIST ver1.0 criteria, adequate organ function, and written informed consent. S-1 (40-60 mg bid) and LV (25 mg bid) were orally administered for 1 week, followed by 1 week rest period. The treatment was repeated until disease progression or unacceptable adverse events. The primary endpoint was the response rate (RR), and the secondary endpoints were efficacy and safety. This trial was supported by Taiho Pharmaceutical CO., LTD. ClinicalTrials.gov Identifier: NCT00891332 Results: From October 2008 to June 2009, 73 pts were enrolled in Japan and China. Of the eligible 71 pts, Japan/China was 32/39; median age was 60 (range 27-84); Male/Female was 38/33, and PS:0/1 was 39/32. RR as primary endpoint was 53.5% (95% CI, 41.3-65.5), and 59.4% in Japan and 48.7%in China; Progression Free Survival(PFS) in Japan and China was 6.3 and 6.8 months; median OS was 29.0 and 20.8 months, respectively. The incidences of grade 3 adverse drug reactions were diarrhea 8.3% (3.1% in Japan, 12.5% in China), stomatitis 8.3% (12.5% and 5.0%), anorexia 2.8% (6.3% and 0.0%), neutropenia 9.7%(9.4% and 10.0%), and there was no treatment-related death. Conclusions: This S-1 plus LV (1week on/ 1 week off) treatment regimen showed promising activity in pts with untreated mCRC without the concurrent use of irinotecan, oxaliplatin, or molecular-targeted drugs in both Japan and China. Clinical trial information: NCT00891332.
American medical oncology physician (AMOP) preferences for combined modality therapy beginning with systemic management in patients with liver-limited metastatic colorectal cancer (LL-mCRC).
Authors: Choti Michael A. , Green Mark R. , Corral Mitra , Wong Schiffon L. , Cairns Jessica , Thomas Michele R. , Eaddy Michael 
Published: February 2017

532 Background: Patients with LL-mCRC are frequently managed with multi-modality therapy, including systemic chemotherapy ± biotherapy. In some settings, surgery is used first followed by systemic therapy. In others, the systemic therapy may be used for initial cytoreduction of both macro- and micro-metastatic disease with surgical consolidation and then observation or further systemic management post-operatively. In the current study, we assessed the preferences of 190 AMOPs in the treatment of patients with LL-mCRC. Methods: AMOPs practicing for ≥5 years and ≤35 years with ≥70% direct patient contact were eligible for study inclusion. To assess preferred sequencing, a single patient profile was created and 10 different sets of de-identified liver CT l images representing a broad spectrum of LL-mCRC were collected. AMOPs independently reviewed each set of liver CT images through a web-based tool and provided their assessment of the immediate resectability of the LL-mCRC shown, as well as their preferred approach to the initial management for that set of scans. Treatment preferences across all scans were presented according to the percentage of AMOPs designating a particular scan as resectable now. Results: Participating AMOPs treated an average of 15.5 mCRC patients per month. Resectability rates and preferences for initial therapy are shown in the Table. Conclusions: AMOPs show an overall preference for initiation of sequencing multi-modality management with systemic therapy across the spectrum of LL-mCRC. [Table: see text]
Obesity and peritoneal surface disease: Outcomes following cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC).
Authors: Votanopoulos Konstantinos I , Swett Katrina R , Swords Doug S , Shen Perry , Stewart John , Levine Edward A. 
Published: February 2017

533 Background: It is estimated that 35% of the US population is obese. It is unknown how obesity influences the operative and survival outcomes of CRS/HIPEC procedures. Methods: A retrospective analysis of a prospective database of 1,000 procedures was performed. Type of malignancy, ECOG, resection status, hospital and ICU stay, Clavien-Dindo morbidity, mortality and survival were reviewed. Results: 242 patients with BMI>30 (30-63.3) underwent 264 CRS/HIPEC procedures between 1991-2012. 94(38.8%) of those had a BMI>35. 136(51.7%) obese patients had appendiceal and 59(22.4%) colon cancer. Median follow up for obese patients was 52 months. Major (III /IV) and minor morbidity (I/II) was 36.6% and 28.8% for obese and 36.5% and 25.7% for non-obese patients. The 30 day mortality for obese and non-obese was 5.5% and 7.3% respectively. Median ICU and hospital stay was 1 and 9 days for both obese and non-obese. The 30 day readmission rate was similar between obese and non-obese patients 35.2% vs 30.8%. When patients were grouped by primary (colon or appendix), resection status, and grade of disease (for appendiceal) and stratified by BMI (not obese, 30-<35, ≥35) there was no difference in 30 day postoperative morbidity and mortality. When the interaction of obesity with the biology of the underlying primary was studied there was no obesity related survival differences. For obese and non-obese patients, median survival for low grade appendiceal cancer was 76 months and 107 months respectively (p=0.38) and for colon cancer was 18.1 months and 19.8 months. 5 and 10 year survival for the low grade appendiceal group was 60.5% and 33.1% for obese and 69.1% and 46.5% for non obese (p=0.38). Conclusions: Obesity does not influence postoperative morbidity and mortality of patients with peritoneal surface disease (PSD) regardless of primary. Obesity does not influence long term survival for appendiceal and colon cancer patients with PSD, and should not be considered a contraindication for the procedure.
Positron emission tomography-computed tomography (PET-CT) for the assessment of pathologic response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma.
Authors: Ashraf Noman , Razzaque Saqib , Creelan Ben C. , Chavez Julio C. , Shibata David , Hoffe Sarah , Shridhar Ravi , Kim Richard D. 
Published: February 2017

537 Background: Preoperative 5-fluorouracil and radiation (FU-XRT) has been demonstrated to improve recurrence-free survival in locally advanced rectal adenocarcinoma, however the role of interval PET-CT remains unclear. We performed a retrospective study with the primary objective of examining the association of change in standardized uptake value (SUV) by PET-CT after neoadjuvant chemoradiation and pathologic complete response (path CR) to survival. Methods: Data was extracted for cases at our institution between August 2006–August 2009, with last follow-up performed July 2012. Patients were included if (i) they had completed a full course of preoperative FU-XRT, followed by surgery with intent for R0 resection, and (ii) pre- and post- therapy PET-CT as well as pathologic reports were available for review. Data was compared by Fischer's exact and Wilcoxon rank-sum, and survival was analyzed using Kaplan-Meier method. Clinicopathologic data was compared by log-rank test and univariate Cox proportional hazards for relationship to overall survival (OS). Results: Of 128 total rectal cancer cases reviewed, 25 (19%) met inclusion criteria. Characteristics of 25 patients included: 13 female, age 57± 14 years (median ± SD). After 116 patient-years of follow-up, median OS was not reached; mean OS was 4.6 ± 0.9 years. Mean baseline pre-treatment PET SUV (18.5 ± 9.1) decreased after neoadjuvant FU-XRT (5.0 ± 4.3, p < 0.0001). Five achieved path CR. Presence of earlier stage was associated with non-significant trend towards improved chance of pathologic CR (RR 3.1, p = 0.07). A decrease in PET SUV by 80% or more was associated with improved odds of path CR (OR 25, 95% CI 1.2 - 513, p = 0.009), and was also associated with a non-significant trend towards improved OS (HR 0.19, 95% CI 0.01 - 2.7). Path CR was associated with a non-statistically significant trend to improved overall survival (HR 0.28, 95% CI 0.01 - 8.4). Conclusions: Reduction in PET-CT SUV after neoadjuvant chemoradiation may be a useful predictor of pathologic CR in rectal adenocarcinoma. These exploratory findings need to be validated in larger prospective studies.
Efficacy of carboplatin and paclitaxel therapy in patients with advanced squamous cell carcinoma (SCC) of the anal canal.
Authors: Byer Jennifer , Mahipal Amit , Dinwoodie William R. , Almhanna Khaldoun , Shibata David , Kim Richard D. 
Published: February 2017

539 Background: Development of distant metastases in SCC of the anal canal is not very common after treatment with combined modality. Only widely published data for treatment of metastatic disease is cisplatin and 5-FU. Carboplatin and paclitaxel is commonly used in squamous cancer of the lung but its efficacy in SCC of the anal cancer is unclear. The objective of this study is to determine the tolerability and outcome of patients with SCC of the anal canal treated with carboplatin/paclitaxel at Moffitt Cancer Center. Methods: Retrospective analysis was conducted looking at Moffitt Cancer tumor registry from 1/2007 to 1/2012. Eligible patients were required to have diagnosis of SCC of the anal cancer and received carboplatin/paclitaxel every 3 weeks as part of the treatment. Results: 13 patients fulfilled the criteria. 11 patients were initially diagnosed with early stage (Stage I-III). 11 patients received concurrent chemo radiation (Nigro regimen or cisplatin + 5-FU) and had reoccurrence. 2 patients were initially diagnosed with Stage IV disease. Median age was 56 years and 77% were females. Upon diagnosis of metastatic disease, 11 patients received prior chemotherapy (cisplatin/5FU, irinotecan/cetuximab, cisplatin/docetaxel). 4/13 patients received 2 prior chemotherapy regimens, 7/13 received only 1 prior regimen and 2/13 did not receive any prior chemotherapy. Patients received an average of 4.7 cycles (1 cycle= 3 weeks). Median was 4 cycles. The response rate was high at 62% with 2 patients achieving complete response and 6 patients with partial response. Grade 3 toxicities included peripheral neuropathy (n= 3), diarrhea (n= 1), and infection (n=3). 4 patients had grade 3 neutropenia and 1 patient had grade 4 anemia. Median progression free survival and overall survival were 4.6 and 10.5 months respectively. Conclusions: Carboplatin and paclitaxel seem to be well tolerated and have activity in the treatment of advanced SCC of the anal canal. Larger studies need to be conducted to validate these findings.